Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-06-14
2011-06-14
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S484000, C514S369000, C514S635000, C514S866000
Reexamination Certificate
active
07959946
ABSTRACT:
A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4166800 (1979-09-01), Fong
patent: 4389330 (1983-06-01), Tice et al.
patent: 4687777 (1987-08-01), Meguro et al.
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4891223 (1990-01-01), Ambegaonkar et al.
patent: 4968507 (1990-11-01), Zentner et al.
patent: 5294770 (1994-03-01), Riddle et al.
patent: 5356913 (1994-10-01), Colca
patent: 5376771 (1994-12-01), Roy
patent: 5478852 (1995-12-01), Olefsky et al.
patent: 5602133 (1997-02-01), Antonucci et al.
patent: 5658474 (1997-08-01), Geerke
patent: 5681584 (1997-10-01), Savastano et al.
patent: 5698220 (1997-12-01), Cardinal et al.
patent: 5719188 (1998-02-01), Colca
patent: 5840335 (1998-11-01), Wenzel et al.
patent: 5859037 (1999-01-01), Whitcomb
patent: 5916584 (1999-06-01), O'Donoghue et al.
patent: 5948440 (1999-09-01), Arora et al.
patent: 5952356 (1999-09-01), Ikeda et al.
patent: 5955106 (1999-09-01), Moeckel et al.
patent: 5965584 (1999-10-01), Ikeda et al.
patent: 6011049 (2000-01-01), Whitcomb
patent: 6031004 (2000-02-01), Timmins et al.
patent: 6099859 (2000-08-01), Cheng et al.
patent: 6099862 (2000-08-01), Chen et al.
patent: 6153632 (2000-11-01), Rieveley
patent: 6166042 (2000-12-01), Ikeda et al.
patent: 6166043 (2000-12-01), Ikeda et al.
patent: 6172090 (2001-01-01), Ikeda et al.
patent: 6191162 (2001-02-01), Byrd et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6291495 (2001-09-01), Rieveley
patent: 6296874 (2001-10-01), Cutie et al.
patent: 6329403 (2001-12-01), Odaka et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6403121 (2002-06-01), Adjei et al.
patent: 6451342 (2002-09-01), Adjei et al.
patent: 6475521 (2002-11-01), Timmins et al.
patent: 6495162 (2002-12-01), Cheng et al.
patent: 6524621 (2003-02-01), Adjei et al.
patent: 6599284 (2003-07-01), Faour
patent: 6660300 (2003-12-01), Timmins et al.
patent: 6780432 (2004-08-01), Cutie et al.
patent: 6790459 (2004-09-01), Cheng et al.
patent: 6838093 (2005-01-01), Flanner et al.
patent: 6866866 (2005-03-01), Chen et al.
patent: 7374779 (2008-05-01), Chen et al.
patent: 2001/0046515 (2001-11-01), Adjei et al.
patent: 2002/0064556 (2002-05-01), Cheng et al.
patent: 2002/0071866 (2002-06-01), Geerke
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0113371 (2003-06-01), Dhawan et al.
patent: 2003/0118647 (2003-06-01), Seth
patent: 2003/0118649 (2003-06-01), Gao et al.
patent: 2003/0224046 (2003-12-01), Rao et al.
patent: 2004/0081697 (2004-04-01), Lewis et al.
patent: 2004/0092531 (2004-05-01), Chizh et al.
patent: 2005/0074490 (2005-04-01), Lin et al.
patent: 2006/0057202 (2006-03-01), Antarkar et al.
patent: 2006/0141023 (2006-06-01), Trehan et al.
patent: 2006/0204578 (2006-09-01), Vergez et al.
patent: 2006/0286168 (2006-12-01), Koike et al.
patent: 1582928 (2005-02-01), None
patent: 0 169 105 (1986-01-01), None
patent: 0 283 369 (1988-09-01), None
patent: 0 381 181 (1995-08-01), None
patent: 0 749 751 (1996-12-01), None
patent: 0 781 129 (1997-07-01), None
patent: 0 753 298 (2001-11-01), None
patent: 1 588 708 (2005-10-01), None
patent: WO 96/09823 (1996-04-01), None
patent: WO 98/11879 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 99/47128 (1999-09-01), None
patent: WO 9947128 (1999-09-01), None
patent: WO 99/55320 (1999-11-01), None
patent: WO 00/28989 (2000-05-01), None
patent: WO 00/72827 (2000-12-01), None
patent: WO 01/35940 (2001-05-01), None
patent: WO 01/35941 (2001-05-01), None
patent: WO 0135940 (2001-05-01), None
patent: WO01/47498 (2001-07-01), None
patent: WO01/74336 (2001-10-01), None
patent: WO 01/82875 (2001-11-01), None
patent: WO0211702 (2002-02-01), None
patent: WO 02/28181 (2002-04-01), None
patent: WO 03/004009 (2003-01-01), None
patent: WO 03/035029 (2003-05-01), None
patent: WO03/004355 (2003-06-01), None
patent: WO 03/047529 (2003-06-01), None
patent: WO 2004/006921 (2004-01-01), None
patent: WO 2004/067001 (2004-08-01), None
patent: WO99/47125 (2005-04-01), None
patent: WO 2005/063226 (2005-07-01), None
patent: WO 2005/110405 (2005-11-01), None
Http://www.answers.com/topic/biguanide-1 (2007).
Http://www.medicinenet.com, (2007). for thiazolidinedione.
Menon et al., The American Journal of Gastroenterology, vol. 96, No. 5, pp. 1631-1634 (2001).
An opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.
A translation of the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.
A response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.
A translation of the response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.
An opposition filed in Chile against a foreign equivalent of the present application, 2008.
A translation of the opposition filed in Chile against a foreign equivalent of the present application, 2008.
A response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.
A translation of the response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.
Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.
Dailey GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review. (Abstract Only) .
Bailey CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance in Type 2 Diabetes, Int J Clin Pract (Sep. 2004) 58(9): 867-76.
Campbell, RK et al., Metformin: A New Oral Biguanide, Clin Ther (May-Jun. 1996); 18(3): 360-71.
Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. (Jan. 1997); 102(1):99-110.
Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (May 1995); 49(5):721-49.
Zimmer Barbara, Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.
Koski, Renee Rae, Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).
Jagoe, Donna, International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Jagoe, Donna, International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Joynes, Robert M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Nickitas-Etienne, Athina, International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, The International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.
Woodward, Michael, International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.
Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).
Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.
Dailey GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review. (Abstract Only).
Bailey CJ, et al. Avandamet: Combined Metformin-Rosiglitazo
Cardinal John R.
Goldfarb Robert I.
Kositprapa Unchalee
Nangia Avinash
Florek & Endres PLLC
Watson Pharmaceuticals, Inc.
Weddington Kevin
LandOfFree
Pharmaceutical formulation containing a biguanide and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulation containing a biguanide and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation containing a biguanide and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683152